Lupin signs exclusive licensing pact with Neopharmed for plasil in Philippines and Brazil

Pharma major Lupin Ltd on Thursday (December 18) said its subsidiaries in the Philippines and Brazil have entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A for marketing and promotional rights of the gastroenterology brand Plasil in their respective markets.

Under the agreement, Lupin’s Philippines subsidiary, Multicare Pharmaceuticals, and its Brazil subsidiary, MedQuimica, will market and promote Plasil, which contains metoclopramide. The arrangement is aimed at strengthening Lupin’s gastroenterology portfolio while expanding its presence across emerging markets.

Neopharmed Gentili will be responsible for overseeing the supply of the product in the Philippines, with a focus on ensuring quality and compliance with global standards. In Brazil, production of the product will be shifted to MedQuimica’s manufacturing facility.

Also Read: Lupin clears major EU regulatory hurdle for biosimilar ranibizumab

Fabrice Egros, President of Corporate Development, Lupin, said, "Our partnership with Neopharmed represents a significant milestone in Lupin’s commitment to expand access to Plasil, one of the most potent anti-emetic treatments, across key emerging markets.

Our extensive local presence, regulatory expertise, and strong commercial capabilities in the Philippines and Brazil, together with Neopharmed’s distribution network and reach, will broaden patient access and deliver meaningful health outcomes."

Matteo Meazzini, Director of Business Development, Neopharmed Gentili, said, "We are pleased to partner with Lupin to bring Plasil to two strategic and rapidly growing markets, such as Brazil and the Philippines. This agreement reflects our commitment to expanding Neopharmed’s international footprint, while leveraging Lupin’s strong local presence to ensure that Plasil is available to every patient in need."

Also Read: Lupin's Nagpur injectable facility secures US FDA VAI classification

Plasil is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients. Shares of Lupin Ltd ended at ₹2,116.00, down by ₹2.90, or 0.14%, on the BSE.